Pharmaceutical AIoT projects are often described in terms of sensors, dashboards, and predictive analytics. Yet one of the most important engineering challenges is less visible: designing a reliable path from an operational event to the information a user can trust.
A sensor reading is not automatically useful business data. It needs context, a timestamp, a source, appropriate quality checks, and a defined relationship to the process being monitored.
This article explores several design considerations for teams building connected pharmaceutical manufacturing systems.
1. Treat an observation as more than a value
Consider a temperature observation.
A value such as 21.5 means very little without knowing the unit, sensor identity, measurement time, location, and intended application.
A conceptual event structure might contain:
- Event identifier
- Sensor or device identifier
- Measurement value and unit
- Event timestamp
- Receipt timestamp
- Location or equipment reference
- Data-quality status
- Schema or message version
The distinction between event time and receipt time is particularly important. Network interruptions can cause delayed messages, and the time a platform receives an observation may differ from the time the measurement was taken.
This example is conceptual; production implementations should define schemas, units, timestamp formats, and validation rules appropriate to their requirements.
2. Design for unreliable connectivity
Connected devices may lose network access, restart, or transmit duplicate messages.
A robust ingestion layer should account for these conditions rather than assuming every event arrives exactly once and in order.
Useful design measures include:
- Stable event identifiers
- Retry policies with appropriate backoff
- Idempotent processing where possible
- Explicit handling of late-arriving events
- Monitoring for missing or stale device data
- Dead-letter or quarantine handling for invalid messages
The goal is to preserve traceability through failures, not simply to keep a dashboard populated.
3. Separate ingestion from business interpretation
A common architectural mistake is to combine raw device ingestion, business rules, and user-facing reporting in one tightly coupled component.
A more maintainable design separates responsibilities:
Device layer: Generates measurements and operational events.
Ingestion layer: Receives messages, checks their structure, and handles transport concerns.
Normalization layer: Applies consistent units, identifiers, timestamps, and schema rules.
Integration layer: Associates events with relevant equipment, locations, production records, or enterprise entities.
Application layer: Presents authorized users with information relevant to their workflows.
This separation makes it easier to test components and evolve integrations without rewriting the entire application.
4. Make data lineage and auditability explicit
Pharmaceutical systems may support processes subject to formal quality and regulatory requirements. Data handling must therefore be designed around the intended use of the system.
Engineering teams should determine which records require audit trails, how corrections are represented, who can modify configuration, and how access is controlled.
Overwriting an original observation without retaining the required history may be inappropriate for certain regulated use cases. A better approach may involve preserving the original event and recording subsequent corrections or annotations with suitable provenance.
The exact requirements depend on the system's intended use and applicable regulations.
5. Integrate with existing systems deliberately
Manufacturing environments may already contain MES, ERP, LIMS, and QMS platforms.
Before building an integration, establish which system is authoritative for each data domain. Define identifier mappings, synchronization expectations, conflict handling, and failure recovery.
For example, an asset-tracking service may report a location event, while an enterprise system remains authoritative for the asset's registered identity or maintenance status.
Clear ownership avoids competing records and makes integration behavior easier to explain.
6. Introduce analytics only after establishing data quality
AI models can help detect unusual patterns or estimate future equipment needs, but their outputs depend on the quality and representativeness of their input data.
Before deployment, teams should assess missing data, sensor drift, changing operating conditions, and the consequences of false positives and false negatives.
Model outputs also need defined handling rules. A prediction that equipment may require inspection should not automatically trigger an unreviewed action affecting a regulated manufacturing process.
Testing, monitoring, documentation, and appropriate human oversight are part of the system design.
7. Build around a measurable use case
A practical project begins with a clearly defined operational objective.
Examples include identifying stale sensor readings, improving visibility into selected equipment, or reducing delays in finding material status information.
Establish a baseline, implement a limited pilot, and measure reliability and workflow impact. Only then should the architecture be expanded.
For a pharmaceutical-specific overview of connected manufacturing applications, see PharmaFlux AI.
The core engineering principle is straightforward: reliable pharmaceutical AIoT depends on trustworthy data pipelines, clear system responsibilities, and carefully controlled use of analytics—not merely on connecting more devices.
Top comments (0)